<SEC-DOCUMENT>0000929638-26-000098.txt : 20260109
<SEC-HEADER>0000929638-26-000098.hdr.sgml : 20260109
<ACCEPTANCE-DATETIME>20260109085956
ACCESSION NUMBER:		0000929638-26-000098
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260109
DATE AS OF CHANGE:		20260109

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aclaris Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001557746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460571712
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89137
		FILM NUMBER:		26521446

	BUSINESS ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		484-324-7933

	MAIL ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bonita Biotech (HK) Ltd
		CENTRAL INDEX KEY:			0002099513
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			K3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2705, 27/F, CHINA RESOURCES BLDG
		STREET 2:		26 HARBOUR RD
		CITY:			WAN CHAI
		PROVINCE COUNTRY:   	K3
		ZIP:			999077
		BUSINESS PHONE:		86-18221753137

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2705, 27/F, CHINA RESOURCES BLDG
		STREET 2:		26 HARBOUR RD
		CITY:			WAN CHAI
		PROVINCE COUNTRY:   	K3
		ZIP:			999077
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0000000000-00-000000</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002099513</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>Common Stock, $0.00001 par value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/09/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001557746</issuerCik>
<issuerName>Aclaris Therapeutics, Inc.</issuerName>
<issuerCusip>00461U105</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>701 Lee Road, Suite 103</com:street1>
<com:city>Wayne</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>19087</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Biosion, Inc.</reportingPersonName>
<citizenshipOrOrganization>F4</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>11281950</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>11281950</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>11281950</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.4</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) Pursuant to the Schedule 13G filed by Biosion, Inc. on November 25, 2024, there were 11,281,985 shares of Common Stock issuable to Biosion, Inc. upon exercise of the Issuer warrant held by it.  Biosion, Inc. assigned the Issuer warrant to its wholly-owned subsidiary, Bonita Biotech (HK) Limited on December 9, 2025, followed by the exercise of the Issuer warrant by Bonita Biotech (HK) Limited by way of cashless exercise in accordance with the terms thereof on December 9, 2025, which resulted in Bonita Biotech (HK) Limited being issued 11,281,950 shares of Common Stock on December 15, 2025.&#13;
(2) Based on 119,624,542 shares of Common Stock of the Issuer, including (i) 108,342,592 shares of Common Stock outstanding as disclosed in the Issuer's current report on Form 8-K filed with the SEC on November 6, 2025, and (ii) 11,281,950 shares of Common Stock issued to Bonita Biotech (HK) Limited upon exercise of the Issuer warrant held by it.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Bonita Biotech (HK) Ltd</reportingPersonName>
<citizenshipOrOrganization>K3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>11281950</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>11281950</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>11281950</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.4</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) Pursuant to the Schedule 13G filed by Biosion, Inc. on November 25, 2024, there were 11,281,985 shares of Common Stock issuable to Biosion, Inc. upon exercise of the Issuer warrant held by it.  Biosion, Inc. assigned the Issuer warrant to its wholly-owned subsidiary, Bonita Biotech (HK) Limited on December 9, 2025, followed by the exercise of the Issuer warrant by Bonita Biotech (HK) Limited by way of cashless exercise in accordance with the terms thereof on December 9, 2025, which resulted in Bonita Biotech (HK) Limited being issued 11,281,950 shares of Common Stock on December 15, 2025.&#13;
(2) Based on 119,624,542 shares of Common Stock of the Issuer, including (i) 108,342,592 shares of Common Stock outstanding as disclosed in the Issuer's current report on Form 8-K filed with the SEC on November 6, 2025, and (ii) 11,281,950 shares of Common Stock issued to Bonita Biotech (HK) Limited upon exercise of the Issuer warrant held by it.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Aclaris Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>701 Lee Road, Suite 103, Wayne, Pennsylvania, 19087</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>1.	Biosion, Inc.&#13;
&#13;
2.	Bonita Biotech (HK) Limited</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>For all reporting persons:&#13;
&#13;
5th Floor, Building D&#13;
3-1 Zhongdan Unit, South Longshan Rd&#13;
Jiangbei New District&#13;
Nanjing, Jiangsu, China</principalBusinessOfficeOrResidenceAddress>
<citizenship>Biosion, Inc. is established under the laws of the People's Republic of China.&#13;
&#13;
Bonita Biotech (HK) Limited is incorporated under the laws of Hong Kong.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>The information for each reporting person contained in Items 5-9 of the cover pages is incorporated herein by reference.</amountBeneficiallyOwned>
<classPercent>The information for each reporting person contained in Item 11 of the cover pages is incorporated herein by reference.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>The information for each reporting person contained in Item 5 of the cover pages is incorporated herein by reference.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>The information for each reporting person contained in Item 6 of the cover pages is incorporated herein by reference.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>The information for each reporting person contained in Item 7 of the cover pages is incorporated herein by reference.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>The information for each reporting person contained in Item 8 of the cover pages is incorporated herein by reference.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>Exhibit 99.1 Joint Filing Agreement</exhibitInfo>
<signatureInformation>
<reportingPersonName>Biosion, Inc.</reportingPersonName>
<signatureDetails>
<signature>/s/ MINGJIU CHEN</signature>
<title>MINGJIU CHEN / CEO</title>
<date>01/09/2026</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Bonita Biotech (HK) Ltd</reportingPersonName>
<signatureDetails>
<signature>/s/ MINGJIU CHEN</signature>
<title>MINGJIU CHEN / Director</title>
<date>01/09/2026</date>
</signatureDetails>
</signatureInformation>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit 99.1</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Joint Filing Agreement</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the
      joint filing, on behalf of each of them, of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value US$0.00001 per share, of Aclaris Therapeutics, Inc.; and (ii) that this joint filing agreement may be
      included as an Exhibit to such joint filing. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it
      contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="margin: 0px 0px 0px 50%; font-weight: bold;">Biosion, Inc.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="margin: 0px 0px 0px 50%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Signature:</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> /s/ MINGJIU CHEN</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="margin: 0px 0px 0px 50%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Name/Title:</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> MINGJIU CHEN / CEO</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="margin: 0px 0px 0px 50%; font-weight: bold;">Bonita Biotech (HK) Limited</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="margin: 0px 0px 0px 50%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Signature:</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> /s/ MINGJIU CHEN</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="margin: 0px 0px 0px 50%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Name/Title:</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> MINGJIU CHEN / Director</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
